| Literature DB >> 34621945 |
Sarah S Lee1, Jing-Yi Chern2, Melissa K Frey3, Ashley Comfort4, Jessica Lee5, Nicole Roselli6, Leslie R Boyd1.
Abstract
OBJECTIVE: To compare perioperative outcomes of the elderly versus non-elderly patients on ERPs undergoing laparotomy for gynecologic surgery.Entities:
Keywords: Elderly patients; Enhanced recovery after surgery; Enhanced recovery pathway; Gynecology; Surgical outcomes
Year: 2021 PMID: 34621945 PMCID: PMC8479239 DOI: 10.1016/j.gore.2021.100862
Source DB: PubMed Journal: Gynecol Oncol Rep ISSN: 2352-5789
Fig. 1Enhanced Recovery Pathway protocol. Our institutional ERP protocol was designed by a multidisciplinary team, with goals of euvolemia, pain control with opioid minimization, and early mobilization.
Demographic characteristics of patients enrolled in the ERP pathway.
| 47 (23–89) | 75 (70–89) | 45 (23–69) | <0.001 | |
| 26.4 (17.0–51.9) | 24.6 (19.1–35.7) | 26.5 (17.0–51.9) | 0.433 | |
| 2 (1–4) | 2 (2–3) | 2 (1–4) | 0.011 | |
| 0 (0–7) | 4 (3–7) | 0 (0–7) | <0.001 | |
| 0.841 | ||||
| White | 81 (42.9) | 72 (41.6) | 9 (56.3) | |
| Black | 63 (33.3) | 4 (25.0) | 59 (34.1) | |
| Asian/ Pacific Islander | 16 (8.5) | 2 (12.5) | 14 (8.1) | |
| American Indian/ Native American | 1 (0.5) | 0 (0.0) | 1 (0.6) | |
| Hispanic | 10 (5.3) | 0 (0.0) | 10 (5.8) | |
| Two or more | 2 (1.1) | 0 (0.0) | 2 (1.2) | |
| Other | 16 (8.5) | 1 (6.3) | 15 (8.7) | |
| <0.001 | ||||
| Medicare | 25 (13.4) | 11 (68.8) | 14 (8.2) | |
| Medicaid | 5 (2.7) | 0 (0.0) | 5 (2.9) | |
| Private | 152 (81.3) | 5 (3.3) | 147 (86.0) | |
| Self-pay | 4 (2.1) | 0 (0.0) | 4 (2.3) | |
| Uninsured | 1 (1.0) | 0 (0.0) | 1 (0.6) | |
| <0.001 | ||||
| Benign gynecology | 85 (45.0) | 0 (0.0) | 85 (49.1) | |
| Gynecologic oncology | 104 (55.0) | 16 (100.0) | 88 (50.9) | |
| Benign | 107 (56.6) | 0 (0.0) | 107 (61.8) | <0.001 |
| Malignant or suspected malignant | 82 (43.4) | 16 (100.0) | 66 (38.2) | |
BMI: body mass index, ASA: American Society of Anesthesologists class, CCI: Charlson Comorbidity Index
Perioperative outcomes of patients on ERP pathway.
| 2 (0–8) | 3 (1–8) | 2 (0–7) | <0.011 | |
| 350 (25–2500) | 300 (50–1200) | 350 (25–2500) | 0.950 | |
| 240.5 (119–571) | 271.5 (152–449) | 232.5 (119–571) | 0.191 | |
| <0.001 | ||||
| Myomectomy | 58 (30.7) | 0 (0.0) | 58 (33.5) | |
| Hysterectomy and BS | 41 (21.7) | 0 (0.0) | 41 (23.7) | |
| Hysterectomy and BSO/USO | 44 (23.3) | 6 (37.5) | 38 (22.0) | |
| Hysterectomy and BSO/USO and LND | 25 (13.2) | 5 (31.3) | 20 (11.6) | |
| BSO/USO and LND | 5 (2.6) | 0 (0.0) | 5 (2.9) | |
| BSO/USO | 10 (5.3) | 2 (12.5) | 8 (4.6) | |
| Ovarian cystectomy | 2 (1.1) | 0 (0.0) | 2 (1.2) | |
| Other debulking | 4 (2.1) | 3 (18.8) | 1 (0.6) | |
| <0.001 | ||||
| Benign | 125 (66.1) | 3 (18.8) | 122 (70.5) | |
| Malignant | 64 (33.9) | 13 (81.3) | 51 (20.5) | |
| 0.084 | ||||
| Uterus | 17 (26.6) | 2 (15.4) | 15 (29.4) | |
| Ovary/ fallopian tube/ primary peritoneal | 39 (60.9) | 8 (61.5) | 31 (60.8) | |
| Cervix | 1 (1.6) | 0 (0.0) | 1 (2.0) | |
| Other | 1 (1.6) | 1 (7.7) | 0 (0.0) | |
| Synchronous | 3 (4.7) | 2 (15.4) | 1 (2.0) | |
| Metastatic | 3 (4.7) | 0 (0.0) | 3 (5.9) | |
| 2.13 ± 1.51 | 1.93 ± 1.41 | 2.15 ± 1.52 | 0.575 | |
| 0.03 ± 0.12 | ‘-0.01 ± 0.19 | 0.04 ± 0.11 | 0.187 | |
BS: bilateral salpingectomy; BSO: bilateral salpingo-oophorectomy; USO: unilateral salpingo-oophorectomy; LND: lymph node dissection.
Differences in lab values calculated from admission values to postoperative day one.
Fig. 2Postoperative pain and opioid use. There was parity in outcomes of subjective patient-reported pain and opioid use.
Intraoperative, postoperative, and 30-day complications of patients on ERP pathway.
| 0.675 | ||||
| None | 171 (90.5) | 14 (87.5) | 157 (90.8) | |
| Intraoperative transfusion | 13 (6.9) | 1 (6.3) | 12 (6.9) | |
| Anesthesia complication | 1 (0.5) | 0 (0.0) | 1 (0.6) | |
| Structural damage | 4 (2.1) | 1 (6.3) | 3 (1.7) | |
| 0.051 | ||||
| None | 141 (76.9) | 8 (50.0) | 133 (76.9) | |
| Grade 1 | 23 (12.2) | 3 (18.8) | 20 (11.6) | |
| Grade 2 | 16 (8.5) | 3 (18.8) | 13 (7.5) | |
| Grade 3A | 5 (2.6) | 2 (12.5) | 3 (1.7) | |
| Grade 3B | 1 (0.5) | 0 (0.0) | 1 (0.6) | |
| Grade 4A | 3 (1.6) | 0 (0.0) | 3 (1.7) | |
| 9 (4.8) | 2 (12.5) | 7 (4.0) | 0.170 | |
| 0.708 | ||||
| None | 177 (93.7) | 15 (93.8) | 162 (93.6) | |
| Grade 1 | 1 (0.5) | 0 (0.0) | 1 (0.6) | |
| Grade 2 | 4 (2.1) | 1 (6.3) | 3 (1.7) | |
| Grade 3A | 4 (2.1) | 0 (0.0) | 4 (2.3) | |
| Grade 3B | 3 (1.6) | 0 (0.0) | 3 (1.7) | |
| Grade 4A | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| 7 (3.7) | 0 (0.0) | 7 (4.0) | 1 | |
| 9 (4.8) | 0 (0.0) | 9 (5.2) | 1 | |
Classified by Clavien-Dindo scale, see interpretation of results.
Serious complications defined by class 3A or above.
Postoperative complications by type of complication.
| Acute kidney injury | 3 | 1 | 2 |
| Urinary retention | 2 | 0 | 2 |
| Acute blood loss anemia | 19 | 5 | 14 |
| Poor pain control | 10 | 1 | 9 |
| Ileus/SBO | 12 | 3 | 9 |
| STEMI | 1 | 0 | 1 |
| Urinary tract infection | 3 | 2 | 1 |
| Re-operation | 1 | 0 | 1 |
| Transient hypoxia | 2 | 0 | 2 |
| Persistent hypotension | 1 | 0 | 1 |
| Nerve compression | 1 | 0 | 1 |
| ICU admission | 2 | 0 | 2 |
| Electrolyte imbalance | 2 | 0 | 2 |
| Pneumothorax | 1 | 0 | 1 |
| Delirium | 1 | 1 | 0 |
| 61 | 13 | 48 | |
| SBO, conservative management | 2 | 0 | 2 |
| SBO requiring reoperation | 2 | 0 | 2 |
| Enterocutaneous fistula | 1 | 0 | 1 |
| Would infection | 4 | 0 | 4 |
| Deep vein thrombosis | 1 | 1 | 0 |
| Fascial dehiscence | 1 | 0 | 1 |
| Urinary tract infection | 1 | 0 | 1 |
| Pelvic abscess | 1 | 0 | 1 |
| Acute blood loss anemia | 1 | 0 | 1 |
| 14 | 1 | 13 | |
SBO: small bowel obstruction; STEMI: ST elevation myocardial infarcton; ICU: intensive care unit.
Logistic regression analysis of factors associated with length of stay greater than 2 days, all cohort.
| 5.88 | 1.29–26.67 | 0.022 | 0.35 | 0.04–3.07 | 0.341 | |
| 2.01 | 1.50–2.68 | <0.001 | 1.64 | 1.03–2.63 | 0.038 | |
| 3.67 | 1.98–6.78 | <0.001 | 2.73 | 1.30–5.74 | 0.008 | |
| 5.69 | 2.94411.00 | <0.001 | 1.56 | 0.59–4.13 | 0.37 | |
| 18.57 | 5.51–62.59 | <0.001 | 17.14 | 4.72–62.32 | <0.001 |
Logistic regression analysis of factors associated with length of stay greater than 2 days, gynecologic oncology cohort only.
| 2.94 | 0.62–13.84 | 0.174 | 0.46 | 0.05–4.32 | 0.497 | |
| 1.65 | 1.19–2.29 | 0.003 | 1.46 | 0.87–2.47 | 0.153 | |
| 3.72 | 1.469.48 | 0.006 | 2.49 | 0.80–7.77 | 0.116 | |
| 24.3 | 3.14.188.02 | 0.002 | 16.56 | 2.03–134.93 | 0.009 |
CCI: Charles Comorbidity Index; ASA: American Society of Anesthesologists class.